ProShare Advisors
AXSM icon

ProShare Advisors’s Axsome Therapeutics AXSM Stock Holding History

ProShare Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Sell
1,685
-6,611
-80% -$1.43M ﹤0.01% 1213
2026
Q1 		$1.4M Sell
8,296
-1,434
-15% -$248K ﹤0.01% 730
2025
Q4 		$1.78M Buy
9,730
+1,032
+12% +$144K ﹤0.01% 708
2025
Q3 		$1.06M Sell
8,698
-1,440
-14% -$162K ﹤0.01% 794
2025
Q2 		$1.06M Sell
10,138
-32
-0.3% -$3.39K ﹤0.01% 800
2025
Q1 		$1.19M Sell
10,170
-2,494
-20% -$284K ﹤0.01% 772
2024
Q4 		$1.07M Buy
12,664
+2,942
+30% +$271K ﹤0.01% 880
2024
Q3 		$874K Buy
9,722
+2,015
+26% +$176K ﹤0.01% 853
2024
Q2 		$620K Sell
7,707
-2,017
-21% -$149K ﹤0.01% 871
2024
Q1 		$776K Buy
9,724
+800
+9% +$67.1K ﹤0.01% 869
2023
Q4 		$710K Buy
8,924
+1,268
+17% +$84.8K ﹤0.01% 858
2023
Q3 		$535K Buy
7,656
+558
+8% +$41.7K ﹤0.01% 893
2023
Q2 		$510K Buy
7,098
+309
+5% +$22.8K ﹤0.01% 945
2023
Q1 		$419K Sell
6,789
-926
-12% -$60.8K ﹤0.01% 994
2022
Q4 		$595K Buy
7,715
+1,047
+16% +$62.6K ﹤0.01% 883
2022
Q3 		$297K Buy
6,668
+415
+7% +$20.7K ﹤0.01% 1160
2022
Q2 		$239K Sell
6,253
-2,865
-31% -$90.6K ﹤0.01% 1352
2022
Q1 		$378K Sell
9,118
-2,265
-20% -$70.2K ﹤0.01% 1476
2021
Q4 		$430K Sell
11,383
-225
-2% -$8.28K ﹤0.01% 1563
2021
Q3 		$383K Sell
11,608
-2,350
-17% -$91.6K ﹤0.01% 1374
2021
Q2 		$942K Buy
13,958
+1,386
+11% +$83.2K ﹤0.01% 1074
2021
Q1 		$712K Buy
12,572
+672
+6% +$47.3K ﹤0.01% 1206
2020
Q4 		$969K Buy
11,900
+2,498
+27% +$187K ﹤0.01% 898
2020
Q3 		$670K Sell
9,402
-291
-3% -$22.7K ﹤0.01% 834
2020
Q2 		$798K Buy
9,693
+3,365
+53% +$259K ﹤0.01% 777
2020
Q1 		$372K Sell
6,328
-4,545
-42% -$370K ﹤0.01% 810
2019
Q4 		$1.12M Buy
+10,873
New +$439K 0.01% 767

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ProShare Advisors's AXSM Position: Q2 2026 in Review

ProShare Advisors reduced its Axsome Therapeutics (AXSM) stake by 80% in Q2 2026, selling an estimated $1.43M and leaving 1,685 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #1213.

ProShare Advisors first reported a position in AXSM in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.78M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • ProShare Advisors held 1,685 shares of Axsome Therapeutics worth $412K as of Q2 2026.
  • ProShare Advisors sold 6,611 Axsome Therapeutics shares in Q2 2026, an estimated $1.43M.
  • Axsome Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1213 holding.
  • ProShare Advisors first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • ProShare Advisors's Axsome Therapeutics position peaked at $1.78M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.